Scotiabank lifts gold price forecast and upgrades Newmont, Barrick
Investing.com - Barclays raised its price target on Cellectis (NASDAQ:CLLS) to $8.00 from $4.00 on Friday, while maintaining an Overweight rating on the stock following the company’s R&D day.
The firm highlighted progress with Cellectis’ lasme-cel (UCART22) therapy, which demonstrated deep responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with complete response rates of 42% at the pivotal dose and 56% in the target population. While the company maintains a "GOOD" Financial Health score on InvestingPro, investors should note its current unprofitable status with an EBITDA of -$33 million.
Cellectis has secured full FDA and EMA alignment on the pivotal Phase 2 trial design, with interim analyses expected in the fourth quarter of 2026 and second quarter of 2027, followed by final analysis in the first quarter of 2028 and a Biologics License Application submission in the second half of 2028. With a beta of 3.07, investors should be aware of the stock’s higher volatility compared to the market. Discover more insights and 10+ additional ProTips with InvestingPro’s comprehensive research report.
Management projected peak sales of approximately $700 million for lasme-cel, with potential to reach up to $1.3 billion through label expansion. Key opinion leaders emphasized the value of allogeneic CAR-T therapy for hematopoietic stem cell transplantation.
Additional highlights from the R&D day included Cellectis’ manufacturing capabilities, its partnership with AstraZeneca, upcoming eti-cel (UCART20x22) data at ASH in relapsed/refractory non-Hodgkin lymphoma, and Phase 1 updates from multiple assets expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.